Corifact Approved for Genetic Bleeding Disorder: MedlinePlus

Corifact Approved for Genetic Bleeding Disorder
Made from donated plasma

URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_108958.html(*this news item will not be available after 05/18/2011)

By Scott Roberts
Thursday, February 17, 2011
Related MedlinePlus Pages

Hemophilia
Medicines


THURSDAY, Feb. 17 (HealthDay News) -- Corifact has been approved by the U.S. Food and Drug Administration to treat congenital Factor XIII deficiency, a rare genetic disorder that could cause life-threatening bleeding. It's also called congenital hemophilia A.

People born with the disorder do not make enough Factor XIII, a clotting ingredient found in most people's blood, the FDA said in a news release. The condition may cause soft-tissue bruising, fatal bleeding inside the head, and in newborns, umbilical cord bleeding.

Corifact was approved as an orphan drug that's intended to treat a rare condition or disease. The FDA said it sanctioned the drug based on a study involving 14 people, including children, who had congenital Factor XIII deficiency. Reported side effects included allergic reactions, chills, fever, headache, and an increase in liver enzymes.

The drug is made from the pooled blood plasma of healthy donors. The FDA said people who use Corifact may wind up creating antibodies that make the drug ineffective, and warned doctors against administering doses higher than those listed on the product's label.

Corifact is made by the German pharmaceutical firm CSL Behring.


HealthDay
Copyright (c) 2011 HealthDay. All rights reserved.
Corifact Approved for Genetic Bleeding Disorder: MedlinePlus